US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.50

+0.39001.34%

Post-market: 29.500.00000.00%16:00 EDT

Volume:23.63K

Turnover:696.09K

Market Cap:- -

PE:- -

High:29.71

Open:29.71

Low:29.30

Close:29.11

Loading ...

Overview Company News Filings

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Firstgroup’s rail division exceeds expectations

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Press Release: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

‘A failed operator’: CrossCountry repeatedly missed own performance targets despite cutting services

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.5,"timestamp":1751054400000,"preClose":29.11,"halted":0,"volume":23629,"hourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.39,"latestTime":"06-27 16:00:00 EDT","open":29.71,"high":29.71,"low":29.3,"amount":696091.5463,"amplitude":0.014085,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":29.11,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":29.22,"preClose":29.09,"latestTime":"09:28 EDT","volume":60,"amount":1753.1999999999998,"timestamp":1751030924719},"postHourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"volumeRatio":1.0280451084091622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0280451084091622,"shares":0,"dividePrice":0,"high":29.71,"amplitude":0.014085,"preClose":29.11,"low":29.3,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.5,"eps":0,"divideRate":0,"volume":23629,"delay":0,"ttmEps":0,"open":29.71,"prevYearClose":25.88,"prevWeekClose":28.65,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.65,"twentyDayClose":28.2522,"sixtyDayClose":27.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529005938","title":"Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2529005938","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529005938?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:00","pubTimestamp":1745492400,"startTime":"0","endTime":"0","summary":"ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients. Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers. SAN DIEGO and CALGARY, AB, April 24, 2025 /PRNewswire/ -- Oncolytics BiotechInc.  , a leading clinical-stage company specializing in immunotherapy for oncology, will presentnew data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology  Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma  - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options.\"Pelareorep continues to deliver encouraging results in pancreatic cancer, where few effective treatments exist,\" said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. \"In multiple studies, pelareorep has repeatedly demonstrated its abil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-showcase-pancreatic-cancer-110000504.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-showcase-pancreatic-cancer-110000504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ORR","ONCY","AIO"],"gpt_icon":0},{"id":"2529260691","title":"HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529260691","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529260691?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:00","pubTimestamp":1745452800,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025  -- HUTCHMED  Limited   today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research  Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois.Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors. SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed  and/or -amplified  NSCLC post-osimertinib  treated with savolitinib  + osi. A phase I open-label positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers. A multi-cohort study of treatment regimens for metastatic colorectal cancer : Subgroup analysis of sequential therapy between fruquintinib and regorafenib. Wangxia Lv, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-highlights-data-presented-aacr-000000843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MT","BK4559","F","LU0320765646.SGD","LU0106831901.USD","LU0052756011.USD","LU0477156953.USD","LU2417539215.USD","PFS","LU1668664300.SGD","LU0648001328.SGD","IE00BSNM7G36.USD","BK4531","LU0980610538.SGD","LU1791807156.HKD","LU2125154935.USD","BK4534","LU2236285917.USD","BK4516","BK4555","LU0098860793.USD","LU1201861249.SGD","LU0130517989.USD","BK4561","LU0162691827.USD","ORR","BK4585","BK4006","LU1162221912.USD","LU1366192091.USD","BK4588","LU2125154778.USD","BK4574","BK4099","LU0130102774.USD","BK4007","LU0310800965.SGD","HCM","LU0170899867.USD","LU2360032135.SGD","LU0128525689.USD","BK4566","BK4207","BK4195","BK4211","BK4504","LU1267930227.SGD","LU2456880835.USD","LU0072461881.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2529668143","title":"Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668143","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668143?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:15","pubTimestamp":1745439300,"startTime":"0","endTime":"0","summary":"Statistically significant and clinically meaningful progression-free survival  and overall survival  data for Zepzelca  and atezolizumab  combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients. Long-term outcomes and survival data for Ziiherahighlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients. Efficacy and safety of dordaviprone  in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data. An oral abstract of the Phase 3 IMforte trial, which showed statistically significant and clinically meaningful survival benefit (progression-free survival (PFS) and overall survival (OS) for the combination of Zepzelca and atezolizumab (Tecentriq) for extensive-stage small cell lung cancer (ES-SCLC) patients receiving treatmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BN0W2V16.EUR","LU0889565916.HKD","OS","IE00BN0W2W23.USD","BK4007","LU0823416689.USD","BK4197","LU0109394709.USD","BK4211","PFS","BK4195","BK4533","BTC","IHC","IE00BN0W2T93.GBP","CPK","BK4532","JAZZ","BK4097","LU0320765992.SGD","ORR","CDC","BK4162"],"gpt_icon":0},{"id":"2529372711","title":"Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372711","media":"CNW Group","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372711?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial. \"This approval marks the first combination treatment of KEYTRUDA and chemotherapy in Canada for patients with malignant pleural mesothelioma,\" says Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute and Associate Professor at the University of Alberta. \"This combination provides a new therapeutic option for this patient group, which has limited options available and may help improve health outcomes.\". The Phase 3 component of the trial enrolled 440 patients, regardless of tumour PD-L1 expression. Patients with autoimmune disease that required systemic therapy within three years of treatment or a medical condition that required immunosuppression were ineligible. Patients were randomized (1:1) to one of the following treatment arms; all study medications were administered via intravenous infusion:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/health-canada-approves-keytruda-plus-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999013999.USD","BK4157","CCTG","LU1066051811.HKD","IE00B19Z4B17.USD","LU0106261372.USD","LU1057294990.SGD","LU2089984988.USD","ORR","BK4211","LU1934455277.USD","LU0965509101.SGD","LU0234572021.USD","AEIS","LU0203347892.USD","LU1430594728.SGD","LU1585245621.USD","LU1066053197.SGD","LU1571399168.USD","LU0965508806.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4516","LU0266013472.USD","BK4203","IE000M9KFDE8.USD","SG9999002224.SGD","HR","LU0965509283.SGD","LU0265550946.USD","LU0006306889.USD","LU1989772840.SGD","BK4588","LU1093756325.SGD","IE00B1BXHZ80.USD","BK4550","LU2461242641.AUD","IE00BBT3K403.USD","BK4148","LU0208291251.USD","PFS","IE00BJT1NW94.SGD","LU1037948897.HKD","IE0009355771.USD","LU1037948541.HKD","MRK","BK4559","OS","LU0203345920.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2529689806","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689806","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689806?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC –。– Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+  mTNBC –。\"These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,\" said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. \"For patients with this difficult to treat type of breast cancer, these results potentially offer a new pathway that may redefine their treatment options.\". The significant and meaningful improvement in PFS demonstrated in ASCENT-04 further reinforces the potential of Trodelvy plus Keytruda as a much-needed new treatment option for patients with previously untreated inoperable  PD-L1+ loca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203345920.USD","BK4203","HR","MCBS","BK4578","IE00BJT1NW94.SGD","OS","SG9999014542.SGD","ADC","CINV","ORR","IE00BSNM7G36.USD","LU0234570918.USD","LU1093756325.SGD","IE00BBT3K403.USD","LU0208291251.USD","LU0861579265.USD","MRK","BK4007","LU0234572021.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4585","LU2106854487.HKD","PFS","LU1162221912.USD","SG9999002232.USD","SG9999002224.SGD","LU1066051225.USD","LU1023059063.AUD","GILD","LU2023250843.SGD","LU0265550359.USD","LU0985320562.USD","PD","IE00BKVL7J92.USD","IE000M9KFDE8.USD","SAR","LU2361045086.USD","LU2087621335.USD","IE00B1BXHZ80.USD","LU0203347892.USD","LU0965509283.SGD","SG9999001176.USD","LU0965508806.USD","LU1069347547.HKD","LU1035773651.USD","LU2112291526.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2528503708","title":"Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2528503708","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528503708?lang=en_us&edition=fundamental","pubTime":"2025-04-20 18:16","pubTimestamp":1745144218,"startTime":"0","endTime":"0","summary":"We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to take a look at where Cogent Biosciences, Inc.  stands against other promising penny stocks.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cogent-biosciences-cogt-among-most-101658942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2463526074.USD","QID","BK4109","ORR","ASH","QLD","USAW.SI","NVIW.SI","PSQ","MNQmain","USJW.SI","SM","SQQQ","BK4505","BK4139","COGT","NQmain","TQQQ","TSYW.SI",".IXIC","BK4213"],"gpt_icon":1},{"id":"2528852180","title":"Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528852180","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528852180?lang=en_us&edition=fundamental","pubTime":"2025-04-18 11:02","pubTimestamp":1744945331,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a look at where Merus  stands against other high short interest stocks to buy now.Aditya Bhave, BofA Securities head of US Economics, joined ‘Power Lunch’ on CNBC on April 17 to talk about whether tariffs are ultimately inflationary, disinflationary, or deflationary. Aditya Bhave responded that the impact depends on the magnitude of the uncertainty shock. He explained that tariffs are generally stagflationary, which means that they contribute to both inflation and economic stagnation. However, he also emphasized that it’s not just the content of the trade policy announcements that matters, but also the disruptive way in which these policies have been communicated, which has increased uncertainty for businesses. He noted that there is a scenario where the uncertainty caused by these policies could outweigh their stagflationary effects, making tariffs disinflationary i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merus-nasdaq-mrus-best-high-030211019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4588","IE00BKPKM429.USD","NVIW.SI","LU2210150020.SGD","MNQmain","TSYW.SI","LU0109394709.USD","LU0320765992.SGD","US7Y.BOND","BK4139","QID","US5Y.BOND","US30Y.BOND","MRUS","US10Y.BOND","BK4112","PSQ","IE00BGHQF748.EUR","US2Y.BOND","TQQQ","IE00B3QW5Z07.USD","US3Y.BOND","US6M.BOND",".IXIC","LU2210149790.SGD","LU0889565916.HKD","SQQQ","NQmain","US12M.BOND","ORR","USAW.SI","BK4585","USJW.SI","NDAQ","QLD","LU2095319765.USD"],"gpt_icon":1},{"id":"2527241400","title":"Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241400","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241400?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:03","pubTimestamp":1744812204,"startTime":"0","endTime":"0","summary":"We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Relay Therapeutics Inc.  stands against other biotech penny stocks.Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he’s credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes.We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relay-therapeutics-inc-nasdaq-rlay-140324064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","TSYW.SI","BK4139","BK4563","BK4195","BK4588","LU2210149790.SGD","SQQQ","NDAQ","USAW.SI","IE00BKPKM429.USD","IE00B64PRP62.GBP","PSQ","NVIW.SI","QID","USJW.SI","BK4585","IE00B3QW5Z07.USD","BK4211",".IXIC","BK4112","IE00BGHQF748.EUR","NQmain","LU2210150020.SGD","LU2095319765.USD","PFS","MNQmain","ORR","RLAY","QLD"],"gpt_icon":1},{"id":"2528051222","title":"Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528051222","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528051222?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:03","pubTimestamp":1744812185,"startTime":"0","endTime":"0","summary":"We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Cogent Biosciences Inc.  stands against other biotech penny stocks.Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he’s credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes.We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cogent-biosciences-inc-nasdaq-cogt-140305485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","BK4505","IE00BGHQF748.EUR","NDAQ",".IXIC","IE00B3QW5Z07.USD","BK4213","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","BK4139","COGT","LU2210150020.SGD","SM","ORR","IE00BKPKM429.USD","BK4112"],"gpt_icon":0},{"id":"2527427555","title":"Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527427555","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527427555?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:05","pubTimestamp":1744747500,"startTime":"0","endTime":"0","summary":"- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April  15, 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3062116/0/en/Cardiff-Oncology-Announces-Completion-of-Enrollment-in-Phase-2-CRDF-004-Trial-Evaluating-Onvansertib-for-the-Treatment-of-First-line-RAS-mutated-Metastatic-Colorectal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107325.USD","LU1854103824.USD","PFS","ORR","BK4512","BK4139","LU1861214812.USD","ON","BK4585","BK4605","BK4195","LU2298322129.HKD","BK4211","BK4588","LU2357305700.SGD","LU1978683503.SGD","LU1720051017.SGD","IE00BD6J9T35.USD","LU1861215975.USD","CRDF","IE00BZ199S13.USD","LU0724618433.USD","LU0348723411.USD","LU1861220033.SGD","LU0124384867.USD","LU1720051108.HKD","LU1861219969.SGD","BK4141","LU1854104046.USD","LU1548497426.USD"],"gpt_icon":0},{"id":"2527491267","title":"Firstgroup’s rail division exceeds expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2527491267","media":"cityam","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527491267?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:09","pubTimestamp":1744715390,"startTime":"0","endTime":"0","summary":"Firstgroup said fees from the Department for Transport ’s contracted train operators had proved higher than previously forecast. Firstgroup’s rail business is trading ahead of expectations despite concerns surrounding the UK government’s wide-reaching railway network reforms.The London-listed firm said on Tuesday that fees from the Department for Transport ’s contracted train operators had proved higher than previously forecast.It has also seen “strong demand” for its open access offering, run by Lumo and Hull Trains. Firstgroup acquired access rights for two new open access services over the half-year period and signed a 500m agreement to lease 14 new UK-manufacturered trains.In First Bus, passenger numbers are forecast to grow around two per cent, with annual revenue in First Bus London expected to grow to between 300m and 350m.It also expects to maintain its adjusted earnings per share in 2026.“We have continued our strong financial and operational delivery in the second half of our","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2025/04/Firstgroup-1-1.jpeg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2025/04/Firstgroup-1-1.jpeg?w=824&h=463&crop=1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/firstgroups-rail-division-exceeds-expectations/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["GBR","BK4213","ORR","BK4233"],"gpt_icon":0},{"id":"2526399577","title":"FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2526399577","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526399577?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:58","pubTimestamp":1744210733,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Tuesday approved Bristol Myers Squibb& Co’s  Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients  with unresectable or metastatic microsatellite instability-high  or mismatch repair deficient  colorectal cancer .The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date.Also Read: Europe Approves Bristol Myers’ Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer. Opdivoas a single agent, or in combination withYervoy, was previously granted accelerated approval in MSI-H/dMMR CRC adult and pediatric patients  that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Price Action: BMY stock is down 5.31% at $50.25 at the last check on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-bristol-myers-opdivo-145853592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","LU0225771236.USD","LU1074936037.SGD","LU0882574055.USD","LU0306807586.USD","LU0321505868.SGD","LU1323610961.USD","LU1868837136.USD","LU1989771016.USD","LU0985481810.HKD","MYE","LU1718418525.SGD","BK4126","LU0225284248.USD","BK4213","LU0306806265.USD","LU2360032135.SGD","LU1868836914.USD","LU0061475181.USD","LU1670710661.SGD","BK4588","LU0321505439.SGD","BK4532","LU2242646821.SGD","LU1670711123.USD","IE00BSNM7G36.USD","BK4559","IE00BJJMRZ35.SGD","LU1093756168.USD","IE00BFTCPJ56.SGD","CRC","BK4534","BMY","BK4211","IE00BFXG1179.USD","BK4195","LU1291159041.SGD","BK4585","LU2133065610.SGD","IE00B2B36J28.USD","LU0114720955.EUR","PFS","LU1032466523.USD","LU1868836591.USD","LU1571399168.USD","LU0266512127.USD","LU1868836757.USD","LU1670711040.USD","LU0456855351.SGD","LU2125154778.USD"],"gpt_icon":0},{"id":"2526658053","title":"CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2526658053","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526658053?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:15","pubTimestamp":1744200900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif., April  09, 2025  (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058386/0/en/CERo-Therapeutics-Holdings-Inc-Announces-Initial-Clinical-Trial-Site-for-its-Phase-1-Clinical-Trial-of-CER-1236-in-Acute-Myeloid-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","ORR","BK4161","BK4218","CR"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","HCC","LU0061475181.USD","LU0225771236.USD","LU0114720955.EUR","LU1032466523.USD","LU1093756168.USD","TEN","CRC","LU1670710661.SGD","LU1093756325.SGD","IE00B2B36J28.USD","HSCT","LU1718418525.SGD","LU2242646821.SGD","LU1261432733.SGD","BK4581","VOD","LU2242652126.USD","OS","IE0009355771.USD","LU1670711040.USD","CRT","BK4006","PFS","BK4132","BK4211","LU1323610961.USD","LU1868837300.USD","LU1670710588.SGD","LU1585245621.USD","LU1868836757.USD","IE0002141913.USD","BMY","LU2133065610.SGD","BK4124","LU0225284248.USD","LU1989771016.USD","BK4534","LU1670711123.USD","ORR","LU0868494617.USD","LU0237698245.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0985481810.HKD","LU1074936037.SGD","LU1868837136.USD","BK4532","BK4195"],"gpt_icon":0},{"id":"2525894773","title":"SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894773","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894773?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:45","pubTimestamp":1744116300,"startTime":"0","endTime":"0","summary":"- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing His","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057624/0/en/SELLAS-Announces-Positive-Overall-Survival-in-Cohort-3-from-the-Ongoing-Phase-2-Trial-of-SLS009-in-r-r-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4139","SLS"],"gpt_icon":0},{"id":"2524220685","title":"ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524220685","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524220685?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746400,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU earlier in the treatment of HR positive, HER2 low breast cancer and broadens the eligible patient population to those with HER2 ultralow disease. HR positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still have some level of HER2 expression. Currently, regardless of HER2 expression, endocrine-based therapies are widely used in the early lines of treatment for HR positive metastatic breast cancer. Following endocrine-based therapy, some patients discontinue treatment, and others are treated with conventional chemotherapy which is associated with poor response rates and outcomes.2,3,4,5. In the DESTINY-Breast06 trial, ENHERT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-approved-eu-first-her2-060000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","BK4195","BK4080","BK4156","ORR","BK4007","BK4203","BK4211","DSNKY","HR","PBD","PFS","ADC","BK4225","BK4231"],"gpt_icon":0},{"id":"2524888213","title":"Press Release: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2524888213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524888213?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:05","pubTimestamp":1743710700,"startTime":"0","endTime":"0","summary":"-- Strategic collaboration with LaunXP for the development of vebreltinib in. combination with an EGFR inhibitor  to bring in $10 million. upfront payment and expand dataset to combination therapy. -- New interim data for the vebreltinib development program, including in. non-CNS MET fusion tumors and non-small cell lung cancer  with MET. reductions expected to provide cash runway into the first quarter of 2026. \"In addition, preliminary results we announced in 2024 for various SPARTA cohorts highlight the opportunity for vebreltinib in the treatment of various tumors with c-Met dysregulation. This includes new interim data for the treatment of NSCLC with MET Amplification, new interim data for the treatment of non-CNS solid tumors with MET fusions, and an incremental update for NSCLC with Met Exon 14 skipping,\" continued Dr. Yu.patient with intrahepatic bile duct cancer). Alongside the","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLMW","LU2065732104.USD","PIPE","PRGS","BK4097","ORR","BK4139","APLM"],"gpt_icon":0},{"id":"2524194196","title":"Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194196","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194196?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053162/0/en/Tovecimig-CTX-009-Meets-Primary-Endpoint-in-the-Ongoing-Randomized-Phase-2-3-Study-in-Patients-with-Biliary-Tract-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4213","IE0002270589.USD","BK4092","BK4161","CR","SD","BK4139","CMPX","OS","IE00B19Z3581.USD","LU1169590202.USD","BK4211","IE00B19Z3B42.SGD","PD","LU1169589451.USD","IE00B7SZLL34.SGD","NE","BTC","PR","BK4023","BK4097","ORR","BK4195"],"gpt_icon":0},{"id":"2523092138","title":"TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092138","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092138?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or af","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","BK4007","BK4231","LU0225284248.USD","LU0234572021.USD","BK4550","SG9999003800.SGD","BK4201","LU0053666078.USD","MAA","ORR","LU0289739699.SGD","BK4585","BK4599","LU0306806265.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0321505868.SGD","SG9999013999.USD","BK4107","ADC","BK4533","LU0321505439.SGD","L","SG9999001176.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU0868494617.USD","BK4592","IE0002270589.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU1883839398.USD","BK4581","LU0170899867.USD","LU1894683264.USD","BK4097","EC","LU0058720904.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","SG9999002224.SGD","BK4080","OS","PFS","LU1066051498.USD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2522325509","title":"‘A failed operator’: CrossCountry repeatedly missed own performance targets despite cutting services","url":"https://stock-news.laohu8.com/highlight/detail?id=2522325509","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522325509?lang=en_us&edition=fundamental","pubTime":"2025-03-28 22:41","pubTimestamp":1743172900,"startTime":"0","endTime":"0","summary":"Comparisons with ORR cancellation data suggest it breached those performance indicators in four of the last five months. Two of the monthly reporting periods saw total cancellations reach 749 and 929, significantly ahead of CrossCountry’s absolute worst benchmark.In the immediate month following the remedial plan, the rail company, a subsidiary of Aviva Group, also breached its targets, cancelling 453 trains, according to the document. This was, however, a month in which travel chaos for many train firms worsened after a pay award to drivers meant many worked fewer overtime shifts.One senior rail industry figure alleged CrossCountry is expected to fail to deliver a full timetable in May, although the operator denies this is the case.The government has previously suggested it could fast-forward nationalising rail operators that fail to hit performance targets.","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2025/03/CrossCountry-2.jpeg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2025/03/CrossCountry-2.jpeg?w=824&h=463&crop=1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/a-failed-operator-crosscountry-repeatedly-missed-own-performance-targets-despite-cutting-services/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}